BACKGROUND: Hirschsprung's disease, or congenital aganglionosis, is a developmental disorder of the enteric nervous system and is the most common cause of intestinal obstruction in neonates and infants. The disease has more than 80% heritability, including significant associations with rare and common sequence variants in genes related to the enteric nervous system, as well as with monogenic and chromosomal syndromes. METHODS: We genotyped and exome-sequenced samples from 190 patients with Hirschsprung's disease to quantify the genetic burden in patients with this condition. DNA sequence variants, large copy-number variants, and karyotype variants in probands were considered to be pathogenic when they were significantly associated with Hirschsprung's disease or another neurodevelopmental disorder. Novel genes were confirmed by functional studies in the mouse and human embryonic gut and in zebrafish embryos. RESULTS: The presence of five or more variants in four noncoding elements defined a widespread risk of Hirschsprung's disease (48.4% of patients and 17.1% of controls; odds ratio, 4.54; 95% confidence interval [CI], 3.19 to 6.46). Rare coding variants in 24 genes that play roles in enteric neural-crest cell fate, 7 of which were novel, were also common (34.7% of patients and 5.0% of controls) and conferred a much greater risk than noncoding variants (odds ratio, 10.02; 95% CI, 6.45 to 15.58). Large copy-number variants, which were present in fewer patients (11.4%, as compared with 0.2% of controls), conferred the highest risk (odds ratio, 63.07; 95% CI, 36.75 to 108.25). At least one identifiable genetic risk factor was found in 72.1% of the patients, and at least 48.4% of patients had a structural or regulatory deficiency in the gene encoding receptor tyrosine kinase (RET). For individual patients, the estimated risk of Hirschsprung's disease ranged from 5.33 cases per 100,000 live births (approximately 1 per 18,800) to 8.38 per 1000 live births (approximately 1 per 120). CONCLUSIONS: Among the patients in our study, Hirschsprung's disease arose from common noncoding variants, rare coding variants, and copy-number variants affecting genes involved in enteric neural-crest cell fate that exacerbate the widespread genetic susceptibility associated with RET. For individual patients, the genotype-specific odds ratios varied by a factor of approximately 67, which provides a basis for risk stratification and genetic counseling. (Funded by the National Institutes of Health.).
BACKGROUND:Hirschsprung's disease, or congenital aganglionosis, is a developmental disorder of the enteric nervous system and is the most common cause of intestinal obstruction in neonates and infants. The disease has more than 80% heritability, including significant associations with rare and common sequence variants in genes related to the enteric nervous system, as well as with monogenic and chromosomal syndromes. METHODS: We genotyped and exome-sequenced samples from 190 patients with Hirschsprung's disease to quantify the genetic burden in patients with this condition. DNA sequence variants, large copy-number variants, and karyotype variants in probands were considered to be pathogenic when they were significantly associated with Hirschsprung's disease or another neurodevelopmental disorder. Novel genes were confirmed by functional studies in the mouse and human embryonic gut and in zebrafish embryos. RESULTS: The presence of five or more variants in four noncoding elements defined a widespread risk of Hirschsprung's disease (48.4% of patients and 17.1% of controls; odds ratio, 4.54; 95% confidence interval [CI], 3.19 to 6.46). Rare coding variants in 24 genes that play roles in enteric neural-crest cell fate, 7 of which were novel, were also common (34.7% of patients and 5.0% of controls) and conferred a much greater risk than noncoding variants (odds ratio, 10.02; 95% CI, 6.45 to 15.58). Large copy-number variants, which were present in fewer patients (11.4%, as compared with 0.2% of controls), conferred the highest risk (odds ratio, 63.07; 95% CI, 36.75 to 108.25). At least one identifiable genetic risk factor was found in 72.1% of the patients, and at least 48.4% of patients had a structural or regulatory deficiency in the gene encoding receptor tyrosine kinase (RET). For individual patients, the estimated risk of Hirschsprung's disease ranged from 5.33 cases per 100,000 live births (approximately 1 per 18,800) to 8.38 per 1000 live births (approximately 1 per 120). CONCLUSIONS: Among the patients in our study, Hirschsprung's disease arose from common noncoding variants, rare coding variants, and copy-number variants affecting genes involved in enteric neural-crest cell fate that exacerbate the widespread genetic susceptibility associated with RET. For individual patients, the genotype-specific odds ratios varied by a factor of approximately 67, which provides a basis for risk stratification and genetic counseling. (Funded by the National Institutes of Health.).
Authors: Eileen Sproat Emison; Andrew S McCallion; Carl S Kashuk; Richard T Bush; Elizabeth Grice; Shin Lin; Matthew E Portnoy; David J Cutler; Eric D Green; Aravinda Chakravarti Journal: Nature Date: 2005-04-14 Impact factor: 49.962
Authors: J Amiel; E Sproat-Emison; M Garcia-Barcelo; F Lantieri; G Burzynski; S Borrego; A Pelet; S Arnold; X Miao; P Griseri; A S Brooks; G Antinolo; L de Pontual; M Clement-Ziza; A Munnich; C Kashuk; K West; K K-Y Wong; S Lyonnet; A Chakravarti; P K-H Tam; I Ceccherini; R M W Hofstra; R Fernandez Journal: J Med Genet Date: 2007-10-26 Impact factor: 6.318
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: Andy Itsara; Gregory M Cooper; Carl Baker; Santhosh Girirajan; Jun Li; Devin Absher; Ronald M Krauss; Richard M Myers; Paul M Ridker; Daniel I Chasman; Heather Mefford; Phyllis Ying; Deborah A Nickerson; Evan E Eichler Journal: Am J Hum Genet Date: 2009-01-22 Impact factor: 11.025
Authors: J R Lupski; R M de Oca-Luna; S Slaugenhaupt; L Pentao; V Guzzetta; B J Trask; O Saucedo-Cardenas; D F Barker; J M Killian; C A Garcia; A Chakravarti; P I Patel Journal: Cell Date: 1991-07-26 Impact factor: 41.582
Authors: Minerva M Carrasquillo; Andrew S McCallion; Erik G Puffenberger; Carl S Kashuk; Nassim Nouri; Aravinda Chakravarti Journal: Nat Genet Date: 2002-09-23 Impact factor: 38.330
Authors: Thuy-Linh Le; Louise Galmiche; Jonathan Levy; Pim Suwannarat; Debby Mei Hellebrekers; Khomgrit Morarach; Franck Boismoreau; Tom Ej Theunissen; Mathilde Lefebvre; Anna Pelet; Jelena Martinovic; Antoinette Gelot; Fabien Guimiot; Amanda Calleroz; Cyril Gitiaux; Marie Hully; Olivier Goulet; Christophe Chardot; Severine Drunat; Yline Capri; Christine Bole-Feysot; Patrick Nitschké; Sandra Whalen; Linda Mouthon; Holly E Babcock; Robert Hofstra; Irenaeus Fm de Coo; Anne-Claude Tabet; Thierry J Molina; Boris Keren; Alice Brooks; Hubert Jm Smeets; Ulrika Marklund; Christopher T Gordon; Stanislas Lyonnet; Jeanne Amiel; Nadège Bondurand Journal: J Clin Invest Date: 2021-03-15 Impact factor: 14.808
Authors: Vishal Shinde; Nara Sobreira; Elizabeth S Wohler; George Maiti; Nan Hu; Giuliana Silvestri; Sonia George; Jonathan Jackson; Aravinda Chakravarti; Colin E Willoughby; Shukti Chakravarti Journal: Hum Mol Genet Date: 2021-05-17 Impact factor: 6.150